A federal jury has found Theranos founder Elizabeth Holmes guilty on four criminal counts tied to a scheme to defraud investors, delivering one of the most consequential verdicts yet against a Silicon Valley founder whose company's technology claims once helped produce a valuation of about $9 billion.

The jury convicted Holmes of one count of conspiracy to commit wire fraud against investors and three substantive wire-fraud counts. The U.S. Attorney's Office said the investor wires connected to the convictions totaled more than $140 million. Jurors acquitted Holmes on patient-related counts and failed to reach a unanimous verdict on three additional investor-fraud counts.

A mixed verdict with a clear criminal finding

The outcome followed a 15-week trial in San Jose and seven days of jury deliberations. A Washington Post account reported that the panel found Holmes guilty on four of the 11 charges it considered after prosecutors argued she knowingly misled investors about the capabilities and commercial readiness of Theranos blood-testing technology.

Holmes was acquitted on charges related to patients and the jury deadlocked on three investor counts, producing a verdict that was neither a full prosecution sweep nor a vindication for the former chief executive. A contemporaneous Guardian report described the conviction as a dramatic conclusion to a trial that placed the culture of startup hype, founder charisma and investor diligence under unusual public examination.

The case turned on what Holmes knew and what she told investors

Theranos promised to run large numbers of laboratory tests from small finger-stick blood samples using proprietary analyzers. The government's case argued that Holmes knew the technology did not perform as represented, knew the company relied heavily on conventional third-party machines and nevertheless presented investors with a much stronger picture of technical performance, validation and business traction.

The Justice Department said trial evidence showed Holmes used direct communications, marketing materials, financial information and statements to the media to induce investments. A Yahoo Finance report emphasized that the jury convicted Holmes of fleecing investors while declining to convict her on the patient-related allegations.

The verdict therefore draws an important legal line. Startup optimism, ambitious projections and technical failure are not themselves crimes. Prosecutors had to persuade jurors that Holmes crossed from aggressive promotion into knowing misrepresentation.

A rare prosecution of a celebrated technology founder

Holmes's rise made the case extraordinary. She founded Theranos after leaving Stanford, attracted prominent directors and investors, and became one of the most visible entrepreneurs in the technology industry. Theranos claimed it could transform laboratory medicine by making blood testing cheaper, faster and less invasive.

A Fortune report noted that the company's peak valuation reached roughly $9 billion and that the trial heard from investors, former employees and business partners. An Associated Press account framed the verdict as a test of whether Silicon Valley's tolerance for bold claims and repeated reinvention could shield executives from ordinary fraud standards.

The implications extend beyond Theranos

The conviction is likely to reverberate through venture capital and startup governance. Investors routinely fund companies before products are mature, and founders are expected to make a forceful case for a future that does not yet exist. The Theranos prosecution, however, has shown that claims about present technical capabilities, existing partnerships, validation and revenue cannot be treated as aspirational storytelling when they are used to obtain money.

That distinction matters especially in health technology, where product performance can affect not only investor returns but patient decisions. A Justice Department case page summarizes the prosecution's allegations and the structure of the charges, underscoring the overlap between technology claims, financial representations and regulated medical testing.

Holmes remains free on bond while the court addresses the unresolved counts and moves toward sentencing. Each conviction carries a potential maximum sentence of 20 years, although the eventual sentence will depend on federal guidelines, loss calculations and other factors.

For Silicon Valley, the immediate lesson is narrower but unmistakable: the mythology of the visionary founder does not displace securities and wire-fraud law. Theranos may have been built around a technology story, but the jury's verdict turned on a much older question—whether people were knowingly told false things in order to obtain their money.